FDA Approves Amphastar Naloxone Nasal Spray

FDA has approved an Amphastar NDA for naloxone hydrochloride nasal spray 4mg, which is delivered using the company’s proprietary nasal delivery device. A company statement says the naloxone spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.

Read more